Omeros (OMER)
(Delayed Data from NSDQ)
$4.87 USD
-0.15 (-2.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $4.85 -0.02 (-0.41%) 6:52 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 141 - 160 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of April 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
April and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMS721 Exploratory TMA Clinical Results Suggest Phase 3 Testing for aHUS, IgAN, and HSCT-TMAs; Reiterate OUTPERFORM and $47 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
Q4/FY 2016 Financials Beat: 2017 Catalysts Include Continued OMIDRIA Growth, OMS721 TMAs Data, - Potential Partnerships
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
2017 Outlook and Model Update; Reiterate OUTPERFORM and $47 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
January and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
December and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q3 OMIDRIA Sales Were In-Line and OMS721 Shines in Multiple Rare Diseases; Reiterate OUTPERFORM but Reducing PT to $47 After OMIDRIA Sales Trim.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L